Literature DB >> 22249264

MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.

S I Rothschild1, M P Tschan, E A Federzoni, R Jaggi, M F Fey, M Gugger, O Gautschi.   

Abstract

The c-Src kinase regulates cancer cell invasion through inhibitor of DNA binding/differentiation 1 (ID1). Src and ID1 are frequently overexpressed in human lung adenocarcinoma. The current study aimed at identifying microRNAs (miRNAs) involved in the Src-ID1 signaling in lung cancer. Incubation of lung cancer cells with the Src inhibitor saracatinib led to the upregulation of several miRNAs including miR-29b, which was the most highly upregulated miRNA with predicted binding to the ID1 3'-untranslated region (UTR). Luciferase reporter assays confirmed direct binding of miR-29b to the ID1 3'-UTR. Expression of miR-29b suppressed ID1 levels and significantly reduced migration and invasion. Expression of antisense-miR-29b (anti-miR-29b), on the other hand, enhanced ID1 mRNA and protein levels, and significantly increased lung cancer cell migration and invasion, a hallmark of the Src-ID1 pathway. The ectopic expression of ID1 in miR-29b-overexpressing cells was able to rescue the migratory potential of these cells. Both, anti-miR-29b and ID1 overexpression diminished the effects of the Src inhibitors saracatinib and dasatinib on migration and invasion. Saracatinib and dasatinib decreased c-Myc transcriptional repression on miR-29b and led to increased ID1 protein levels, whereas forced expression of c-Myc repressed miR-29b and induced ID1. In agreement, we showed direct recruitment of c-Myc to the miR-29b promoter. miR-29b was significantly downregulated in primary lung adenocarcinoma samples compared with matched alveolar lung tissue, and miR-29b expression was a significant prognostic factor for patient outcome. These results suggest that miR-29b is involved in the Src-ID1 signaling pathway, is dysregulated in lung adenocarcinoma and is a potential predictive marker for Src kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249264     DOI: 10.1038/onc.2011.578

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

1.  Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia.

Authors:  Jing-Dong Zhou; Lei Yang; Xiao-Wen Zhu; Xiang-Mei Wen; Jing Yang; Hong Guo; Qin Chen; Dong-Ming Yao; Ji-Chun Ma; Jiang Lin; Jun Qian
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 2.  The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

Authors:  Anna Lasorella; Robert Benezra; Antonio Iavarone
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

3.  c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT.

Authors:  D-W Wu; N-Y Hsu; Y-C Wang; M-C Lee; Y-W Cheng; C-Y Chen; H Lee
Journal:  Oncogene       Date:  2014-06-09       Impact factor: 9.867

4.  miR-297 acts as an oncogene by targeting GPC5 in lung adenocarcinoma.

Authors:  Yunchuan Sun; Jianyong Zhao; Xiaoming Yin; Xiangkun Yuan; Jianfei Guo; Jianqiang Bi
Journal:  Cell Prolif       Date:  2016-08-24       Impact factor: 6.831

Review 5.  MicroRNA as tools and therapeutics in lung cancer.

Authors:  Jennifer F Barger; S Patrick Nana-Sinkam
Journal:  Respir Med       Date:  2015-02-19       Impact factor: 3.415

6.  Surface-mediated nucleic acid delivery by lipoplexes prepared in microwell arrays.

Authors:  Yun Wu; Megan Cavanaugh Terp; Kwang Joo Kwak; Daniel Gallego-Perez; Serge P Nana-Sinkam; L James Lee
Journal:  Small       Date:  2013-03-08       Impact factor: 13.281

7.  miR-873 induces lung adenocarcinoma cell proliferation and migration by targeting SRCIN1.

Authors:  Yushun Gao; Qi Xue; Dali Wang; Minjun Du; Yanjiao Zhang; Shugeng Gao
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

8.  miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.

Authors:  C-J Kao; A Martiniez; X-B Shi; J Yang; C P Evans; A Dobi; R W deVere White; H-J Kung
Journal:  Oncogene       Date:  2013-06-03       Impact factor: 9.867

9.  A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers.

Authors:  Christopher L Plaisier; Min Pan; Nitin S Baliga
Journal:  Genome Res       Date:  2012-06-28       Impact factor: 9.043

10.  Epigenetic Therapy in Lung Cancer - Role of microRNAs.

Authors:  Sacha I Rothschild
Journal:  Front Oncol       Date:  2013-06-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.